Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine (LZ901) in Subjects Aged 50 to 70 Years Inclusive
NCT05750017 is registered in ClinicalTrials.gov with Beijing Luzhu Biotechnology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine (LZ901) in Subjects Aged 50 to 70 Years Inclusive
- Lead sponsor
- Beijing Luzhu Biotechnology Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- March 23, 2023
- Completion date
- March 15, 2024
- Enrollment
- 66 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.